Extended table of contents

| Acknowledgements                          | 5 |
| Foreword by the Directors-General         | 6 |
| An integrated health, trade and IP approach to respond to the COVID-19 pandemic | 7 |
| Executive Summary                         | 16 |

**I. Medical technologies: the fundamentals**

| A. Public health and medical technologies: the imperative for international cooperation | 26 |
| 1. Policy coherence                       | 26 |
| 2. Scope of the study                     | 27 |
| 3. The need for this study                | 27 |
| 4. Who should read this study?            | 28 |
| B. The cooperating agencies: the WHO, WIPO and the WTO | 29 |
| 1. World Health Organization              | 29 |
| 2. World Intellectual Property Organization | 30 |
| 3. World Trade Organization               | 31 |
| 4. Trilateral cooperation                 | 31 |
| 5. Other international key stakeholders   | 32 |
| C. The global burden of disease and global health risks | 33 |
| 1. Current estimates of global and regional burden of disease | 33 |
| 2. Trends: major cause groups contributing to the total disease burden | 33 |
| 3. Trends in global health risks          | 35 |
| D. Factors shaping public health policy   | 36 |
| 1. Seeking effective outcomes within a complex policy environment | 36 |
| 2. Transforming policy intersections      | 36 |
| 3. Building stronger links between local, national and global levels | 37 |
| 4. The empirical challenge: an accessible base for policy | 39 |

**II. The policy context for action on innovation and access**

| A. Public health policy                   | 44 |
| 1. Health and human rights                | 44 |
| 2. Access to essential medicines: an indicator for the fulfilment of the right to health | 46 |
| 3. Universal access and the UN Sustainable Development Goals | 46 |
| 4. Public health, innovation and access in the WHO | 48 |
| (a) Resolutions dealing with public health, intellectual property and trade | 48 |
| (b) The Commission on Intellectual Property Rights, Innovation and Public Health | 49 |
| (c) The Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property | 49 |
| (d) Other developments in the WHO         | 50 |
5. Cross-cutting efforts to tackle antimicrobial resistance

6. Regulation of health technologies
   (a) Why regulate medical products?
   (b) Clinical trials
   (c) Research ethics
      (i) Clinical trial ethics
      (ii) Health databases and biobanks
      (iii) Bioethics
   (d) Biotherapeutic products
      (i) Background
      (ii) Pathways for the registration of biotherapeutic products
      (iii) What will be the effect of SBPs on prices?
   (e) Future of regulation
   (f) Regulatory exclusivities
   (g) Patent linkage

B. Intellectual property, trade and other policy dimensions

1. Intellectual property systems
   (a) Introduction to IP systems
   (b) Patent law and policy
      (i) The rationale of the patent system
      (ii) The international framework
      (iii) Basic patent issues
      (iv) Patent procedures
      (v) Review procedures
      (vi) Rights conferred by a patent
      (vii) Exceptions and limitations to patent rights
      (viii) Patent information
      (ix) Patent status and legal status information
      (x) Patent landscapes and medical technologies
      (xi) Filing trends under the Patent Cooperation Treaty system
   (c) Protection of test data
      (i) How test data are protected
      (ii) Innovation and access dimensions
      (iii) Distinction between the protection of patents and of test data
      (iv) Open access to test data
   (d) Trademarks
      (i) The trademark system
      (ii) Trademarks and international non-proprietary names (INNs) for active pharmaceutical ingredients
      (iii) Trademarks and unfair competition
(iv) Regulatory approval of proprietary names 86
(v) Trademark cluttering 86
(vi) Non-traditional marks 86
(vii) Standardized packaging 87
(e) Copyright 87
   (i) Copyright and pharmaceutical package inserts 87
   (ii) Exceptions and limitations – text and data mining 88
   (iii) Licensing schemes 88
   (iv) Orphan works access licensing schemes 88
   (v) Software licensing and eHealth 88
(f) Enforcement 89
   (i) The link between intellectual property right enforcement and public health 90
   (ii) Enforcement provisions of the TRIPS Agreement 90
   (iii) The WIPO Advisory Committee on Enforcement 90
(g) Flexibilities under the TRIPS Agreement and the Doha Declaration 90
   (i) Flexibilities in the IP system 90
   (ii) Background to the Doha Declaration 91
   (iii) Content of the Doha Declaration 93
   (iv) Implementation of the Doha Declaration 93
   (v) Least-developed country transition periods 94
(h) Terms of accession to the WTO 94

2. Competition law and policy 95
   (a) The dual function of competition law and policy 95
   (b) The interface between competition law and policy, and IP protection 96
      (i) Addressing competition policy concerns in the legal framework for IP protection 96
      (ii) Enforcing competition law in the IP context 97
   (c) Preserving innovation: merger control in the pharmaceutical sector 97
   (d) Unfair competition 98

3. Trade policy settings 98
   (a) Tariffs 98
   (b) Non-tariff measures 99
      (i) Sanitary and phytosanitary measures 99
      (ii) Technical barriers to trade 99
   (c) Trade in services 100
      (i) The multilateral legal framework 101
      (ii) The scope of GATS commitments in health-related sectors 101
      (iii) The growing economic importance of trade in health services and the impact of GATS commitments 102
      (iv) Challenges linked to the opening of trade in health services 102
### 4. Government procurement

(a) The importance of a transparent and competitive procurement process for the health sector

(b) Procurement of medical technologies and health services under the GPA

(i) GPA coverage

(ii) The magnitude of GPA parties’ health-related procurement

### 5. Free trade agreements

(a) Trends in trade negotiations beyond the multilateral arena

(b) The non-discrimination principles and FTAs

(c) Intellectual property standards

(d) Investor–state dispute settlement

(e) Commitments in other areas

### 6. Resolving trade disputes at the WTO

### C. Economics of innovation and access to medical technologies

### D. Genetic resources, traditional knowledge and traditional medicine

1. Traditional medicine knowledge systems

2. Traditional medical knowledge in health and IP policy

3. Traditional medicines regulation

4. Concerns about misappropriation of traditional knowledge and genetic resources

5. New approaches to IP protection of traditional medical knowledge

(a) Why protect traditional knowledge?

(b) What is to be protected, and for whose benefit?

(c) What is it to be protected from?

(d) How can traditional knowledge be protected?

(e) Documentation

### III. Medical technologies: the innovation dimension

#### A. Historical pattern of medical R&D

1. Innovation for medical technologies in context

2. From early discoveries to “wonder drugs”

3. Growth and evolution of the pharmaceutical industry

4. From non-exclusive licensing to restricted production

5. Trends in R&D

#### B. The current R&D landscape

1. A time of challenges and opportunities for pharmaceutical R&D

2. The key role of public-sector research in medical R&D

3. Medical R&D costs

4. Incentive models in the innovation cycle

(a) The innovation cycle

(b) Absence of self-sustaining innovation cycle in the case of small markets, low incomes or low sales volumes
### C. Overcoming market failures in medical product R&D

1. Diseases disproportionately affecting people in developing countries  
2. Antimicrobials and antimicrobial resistance  
3. The WHO R&D Blueprint for Action to Prevent Epidemics  
4. WHO Expert Working Groups on R&D financing  
5. Novel approaches to biomedical R&D
   - (a) Monitoring health R&D  
   - (b) Grants  
   - (c) Prizes  
   - (d) Advance market commitments and advance purchase commitments  
   - (e) Priority review vouchers  
   - (f) Tax breaks for companies  
   - (g) Patent pools  
   - (h) Open source drug discovery and development
      - (i) A global binding framework for R&D and a pooled fund for R&D

6. Research for neglected diseases: the role of pharmaceutical companies  
7. WIPO Re:Search – Mobilizing intellectual property for global health

### D. Intellectual property rights in the innovation cycle

1. IP management within the broader legal and policy framework at national and international levels  
2. Intellectual property and the product development process  
3. Patent filing strategies in the public and private sectors and the exercise of patent rights
   - (a) Patenting material that exists in nature  
   - (b) Incremental innovation and evergreening
      - (i) Examples of incremental innovation  
      - (ii) Evergreening  
   - (c) Medical indication claims

4. Pre-grant issues: questions of patentability
   - (a) Patenting material that exists in nature  
   - (b) Incremental innovation and evergreening
      - (i) Examples of incremental innovation  
      - (ii) Evergreening

5. Post-grant issues: questions related to the use of patents
   - (a) Research exception  
   - (b) Research tools  
   - (c) Licensing and assignment with respect to innovation  
   - (d) Patents in R&D agreements and other forms of collaboration
### E. Sharing of influenza viruses and access to vaccines and other benefits

1. WHO Global Influenza Surveillance and Response System
2. Intellectual property rights in the context of PIP negotiations
3. The PIP Framework
4. The PIP Framework and genetic sequence data

### IV. Medical technologies: the access dimension

#### A. The context: health-systems-related determinants of access

1. Universal health coverage
2. International access frameworks: the value chain of medicines and health products
3. The meaning and measurement of "access"
   - Affordability
   - Availability
4. Generic medicines policies, price controls and reference pricing
   (a) Generic medicines policies
      (i) Supply-side measures
      (ii) Demand-side measures
      (iii) A comparison of selected generic medicines policies
   (b) Price control
   (c) Reference pricing
      (i) External reference pricing
      (ii) Internal reference pricing
   (d) Health technology assessments
   (e) Market entry agreements (MEAs)
      (i) Volume limitations
      (ii) Health-outcome-based agreements
   (f) Transparency across the value chain of medicines and health products
   (g) Differential pricing strategies
4. Taxes
5. Mark-ups
6. Rational selection and use of medicines
7. Effective and efficient procurement mechanisms
   (a) Principles for effective procurement
   (b) Tendering
   (c) Procurement and patent information

(e) Patent clusters and patent thickets
(f) Freedom-to-operate issues
   (i) Defining freedom to operate
   (ii) Freedom-to-operate strategies
9. Sustainable financing

10. Manufacturing and technology transfer

11. Regulatory mechanisms and access to medical technologies
   (a) WHO prequalification
   (b) Regulation of medical devices
   (c) Quality assurance by national medicines regulatory authorities
   (d) Regulatory cooperation and convergence: reducing barriers from technical regulations and assessment procedures
   (e) Collaborative procedures for accelerated registration

12. Substandard and falsified (SF) medical products
   (a) Types of SF medical products
   (b) Counterfeit medical products and the TRIPS Agreement
   (c) The impact of SF medicines
   (d) How can SF medical products be combated?

B. Access to health products in specific areas

1. HIV/AIDS
2. Antimicrobial resistance
3. Tuberculosis
4. Non-communicable diseases
5. Hepatitis C virus
6. Paediatric medicines
7. Vaccines
8. Medical devices

C. Intellectual-property-related determinants of access

1. Determinants of access prior to patent grant
   (a) Diagnostic, surgical or therapeutic methods for the treatment of humans or animals
   (b) Patent examination and patent registration
   (c) Patent quality

2. Pre-grant and post-grant review procedures
3. Post-grant determinants of access
   (a) Exceptions and limitations to patent rights
      (i) Regulatory review (or “Bolar”) exception
      (ii) Compulsory licensing and government use
      (iii) The Special Compulsory Licensing System: an additional flexibility aimed at enhancing access to medicines
   (b) Voluntary licensing agreements
   (c) Socially responsible licensing policies and management of IP developed at public institutions
### 4. Patent information and its relationship with public health policy

#### 5. Review of relevant provisions in free trade agreements

<table>
<thead>
<tr>
<th>(a)</th>
<th>Review of selected IP provisions</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i)</td>
<td>Patent law</td>
</tr>
<tr>
<td>(ii)</td>
<td>Patent term extension</td>
</tr>
<tr>
<td>(iii)</td>
<td>Grounds for granting compulsory licences</td>
</tr>
<tr>
<td>(iv)</td>
<td>Exhaustion regime</td>
</tr>
<tr>
<td>(v)</td>
<td>Regulatory exclusivities</td>
</tr>
<tr>
<td>(vi)</td>
<td>Patent linkage</td>
</tr>
<tr>
<td>(vii)</td>
<td>Enforcement</td>
</tr>
<tr>
<td>(viii)</td>
<td>Reaffirmation of TRIPS flexibilities and Doha Declaration principles</td>
</tr>
</tbody>
</table>

| (b) | Investor–state dispute settlement |
| (c) | Major actors in FTAs |
| (d) | Economic impact analysis |
| (e) | The role of international organizations |

### Other trade-related determinants of access

| 1. | International trade and tariff data of health products |
| (a) | International trade in health-related products |
| (b) | Tariff policy for health-related products |
| 2. | Competition law and policy |
| (a) | Application of competition law and policy to manufacturers of originator products |
| (i) | Strategic patenting |
| (ii) | Patent litigation |
| (iii) | Refusal to deal and restrictive licensing practices as abuse of dominance |
| (iv) | Interface of regulatory systems and competition law |
| (b) | Competition law and policy in relation to the generics sector |
| (c) | Application of competition policy to other actors in the health sector |
| (d) | The role of competition policy with regard to public procurement markets |
## Annex I. Resolutions of the UN General Assembly and UN Human Rights Council

### Key Reports of the UN Special Rapporteur on the Right to Health

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selected Resolutions of the United Nations General Assembly</td>
<td>294</td>
</tr>
<tr>
<td>Selected Resolutions of the United Nations Human Rights Council</td>
<td>295</td>
</tr>
<tr>
<td>Key Reports of the United Nations Special Rapporteur on the Right to Health</td>
<td>296</td>
</tr>
</tbody>
</table>

## Annex II. Selected Resolutions and Decisions of the World Health Assembly

## Annex III. Special Compulsory Licences for Export of Medicines

### A. Operation of the System: context and scope

1. What Is the System?  
2. What products are covered by the System?

### B. Legal basis

### C. Use of the System

1. Who can use the System as importers and exporters?  
2. How can the System be used by WTO members?  
   (a) How does an importing member use the System?  
   (i) Notifying general intention to use the System  
   (ii) Notifying the need to import specific pharmaceutical products
   (b) How does an exporting member use the System?

3. Do regulatory authorities have to approve products manufactured under a special compulsory licence?  
4. Which safeguards against diversion need to be put in place?  
5. How can the System be used at the regional level?  
6. What does the WTO General Council Chairman’s statement add?

### D. Domestic implementation

1. Importing members  
2. Exporting members  
3. Regional mechanism

### Bibliography

### Abbreviations

### List of figures, tables and boxes

### Extended table of contents